BriaCell Therapeutics Corp.
TSX: BCT.TO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Toronto Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- William V. Williams
- Employees
- 16
- Headquarters
- West Vancouver, Canada
- IPO year
- 2012
- Market cap
- CA$10.8M
- Website
- https://www.briacell.com
Loading BCT…
Loading profile data…Frequently asked questions about BCT
What does BriaCell Therapeutics Corp. (BCT.TO) do?
BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also d...
Where does BCT.TO trade?
BriaCell Therapeutics Corp. (BCT.TO) trades on the Toronto Stock Exchange.
What sector is BCT.TO in?
BriaCell Therapeutics Corp. (BCT.TO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BriaCell Therapeutics Corp.?
William V. Williams is the chief executive officer of BriaCell Therapeutics Corp. (BCT.TO).
Where is BriaCell Therapeutics Corp. headquartered?
BriaCell Therapeutics Corp. is headquartered in Canada.
Does BCT.TO pay a dividend?
BriaCell Therapeutics Corp. (BCT.TO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BCT.TO go public?
BriaCell Therapeutics Corp. (BCT.TO) completed its initial public offering in 2012.